Onward Gibson Chironda- AVAC Fellow, Zimbabwe Zimbabwe approved cabotegravir long-acting (CAB-LA) for HIV prevention. In March 2021, the Medicines Control Authority of Zimbabwe (MCAZ) approved CAB-LA for use as HIV pre-exposure prophylaxis (PrEP) in combination with oral emtricitabine/tenofovir disoproxil fumarate (FTC/TDF). This landmark approval made Zimbabwe the second country in sub-Saharan Africa, after South Africa, to approve CAB-LA for HIV prevention. The approval of CAB-LA in Zimbabwe is a significant step forward in the country’s efforts to close the tap and the leaks reduce new HIV infections. Zimbabwe has one of…
Read MoreCAB-LA Game Changer for Closing the Leaks to New HIV Infections among young people
